Respiratory syncytial virus (RSV) has eluded active vaccination efforts for more than five
decades and continues to cause substantial morbidity and mortality in infants, the …

Neonates are particularly susceptible to infection. This vulnerability occurs despite their
responsiveness to most vaccines. However, current vaccines do not target the pathogens …

Die Impfempfehlungen der Ständigen Impfkommission (STIKO) wurden auf der 106. Sitzung
der STIKO verabschiedet. Die folgenden Ausführungen ersetzen die im Epidemiologischen …

Background In a phase 1/2 study, a maternal respiratory syncytial virus vaccine candidate
(RSVPreF3) demonstrated an acceptable safety profile and efficiently increased RSV …

Respiratory infectious diseases encountered early in life may result in life-threatening
disease in neonates, which is primarily explained by the relatively naive neonatal immune …

Background Pregnant persons are at increased risk of severe coronavirus disease 2019
(COVID-19) and adverse obstetric outcomes. Understanding maternal antibody response …

Effective strategies are urgently needed to decrease the risk of untoward outcomes of
pregnant women with severe acute respiratory syndrome coronavirus 2 (coronavirus …

Background This study evaluated the safety and immunogenicity of an investigational
trivalent group B streptococcus (GBS) vaccine in US pregnant women, transplacental …

Background Prevention of respiratory syncytial virus (RSV) disease in infants is an unmet
vaccine need, and maternal immunization is a potential strategy to address this need. This …

Background Respiratory syncytial virus (RSV) causes respiratory tract infections, which may
require hospitalization especially in early infancy. Transplacental transfer of RSV antibodies …